Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 06, 2008. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 950,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,182.26 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.10% of total voting rights).
- Shares in Issue: 5,213,313,124 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding share capital through the cancellation of 950,000 repurchased shares. Consequently, the Company's Treasury shareholding now represents 9.10% of total voting rights. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total cost of the 950,000 share repurchase based on the stated price of 1,182.26 pence.
- Confirm the updated total voting rights denominator (5,213,313,124 shares) for disclosure threshold calculations.
- Review the impact of the 9.10% Treasury shareholding on future earnings per share (EPS) metrics.
- Check subsequent filings for the status of the remaining authorized share buyback program.